Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (281-290 of 387) with videos related to

Pageof 39
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
Blood|May 24, 2013
Outcomes of patients with POEMS syndrome treated initially with radiationMichael S Humeniuk, Morie A Gertz, Martha Q Lacy, et al.
British Journal of Haematology|April 14, 2006
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaIrene M Ghobrial, Rafael Fonseca, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemiaTait D Shanafelt, Thomas E Witzig, Stephanie R Fink, et al.
Blood Cancer Journal|August 3, 2018
History of autoimmune conditions and lymphoma prognosisGeffen Kleinstern, Matthew J Maurer, Mark Liebow, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myelomaPrashant Kapoor, Shaji K Kumar, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II studyGrzegorz S Nowakowski, Betsy LaPlant, William R Macon, et al.
British Journal of Haematology|March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypesGeorge A Cholack, Raphael Mwangi, Prokop Vodička, et al.
Pageof 39

Showing results (281-290 of 387) with videos related to

Sort By:
Pageof 39
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
Blood|May 24, 2013
Outcomes of patients with POEMS syndrome treated initially with radiationMichael S Humeniuk, Morie A Gertz, Martha Q Lacy, et al.
British Journal of Haematology|April 14, 2006
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaIrene M Ghobrial, Rafael Fonseca, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemiaTait D Shanafelt, Thomas E Witzig, Stephanie R Fink, et al.
Blood Cancer Journal|August 3, 2018
History of autoimmune conditions and lymphoma prognosisGeffen Kleinstern, Matthew J Maurer, Mark Liebow, et al.
Mayo Clinic Proceedings|October 3, 2007
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myelomaMartha Q Lacy, Morie A Gertz, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myelomaPrashant Kapoor, Shaji K Kumar, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II studyGrzegorz S Nowakowski, Betsy LaPlant, William R Macon, et al.
British Journal of Haematology|March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypesGeorge A Cholack, Raphael Mwangi, Prokop Vodička, et al.
Pageof 39